Scleroderma Induced by Pembrolizumab: A Case Series

被引：71

作者：

Barbosa, Naiara S. ^{[1
]}

Wetter, David A. ^{[1
]}

Wieland, Carilyn N. ^{[1
,2
]}

Shenoy, Niraj K. ^{[3
,4
]}

Markovic, Svetomir N. ^{[3
,4
,5
]}

Thanarajasingam, Uma ^{[6
]}

机构：

[1] Mayo Clin, Dept Dermatol, Rochester, MN USA

[2] Mayo Clin, Div Anat Pathol, Rochester, MN USA

[3] Mayo Clin, Div Hematol, Rochester, MN USA

[4] Mayo Clin, Div Med Oncol, Rochester, MN USA

[5] Mayo Clin, Clin Immunol & Immunotherapeut Program, Rochester, MN USA

[6] Mayo Clin, Div Rheumatol, 200 First St SW, Rochester, MN 55905 USA

来源：

MAYO CLINIC PROCEEDINGS | 2017年 / 92卷 / 07期

关键词：

IMMUNE-CHECKPOINT INHIBITORS; ADVERSE EVENTS; ADVANCED MELANOMA; PD-1; PATHWAYS; IPILIMUMAB; BLOCKADE; CTLA-4; MANAGEMENT; NIVOLUMAB; THERAPY;

D O I：

10.1016/j.mayocp.2017.03.016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease. (C) 2017 Mayo Foundation for Medical Education and Research

引用

收藏

页码：1158 / 1163

页数：6

相关论文

共 21 条

[1] Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade [J].

Ali, Shirwa Sheik ;

Goddard, Allison L. ;

Luke, Jason J. ;

Donahue, Hilary ;

Todd, Derrick J. ;

Werchniak, Andrew ;

Vleugels, Ruth Ann .

JAMA DERMATOLOGY, 2015, 151 (02) :195-199

[2] Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort [J].

Ascierto, Paolo A. ;

Simeone, Ester ;

Sileni, Vanna Chiarion ;

Pigozzo, Jacopo ;

Maio, Michele ;

Altomonte, Maresa ;

Del Vecchio, Michele ;

Di Guardo, Lorenza ;

Marchetti, Paolo ;

Ridolfi, Ruggero ;

Cognetti, Francesco ;

Testori, Alessandro ;

Bernengo, Maria Grazia ;

Guida, Michele ;

Marconcini, Riccardo ;

Mandala, Mario ;

Cimminiello, Carolina ;

Rinaldi, Gaetana ;

Aglietta, Massimo ;

Queirolo, Paola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[3] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[4] Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab [J].

Cappelli, Laura C. ;

Gutierrez, Anna Kristina ;

Baer, Alan N. ;

Albayda, Jemima ;

Manno, Rebecca L. ;

Haque, Uzma ;

Lipson, Evan J. ;

Bleich, Karen B. ;

Shah, Ami A. ;

Naidoo, Jarushka ;

Brahmer, Julie R. ;

Le, Dung ;

Bingham, Clifton, III .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :43-50

[5]

Cappelli LC, 2016, ARTHRITIS CARE RES H, DOI [10.1002/acr.23177, DOI 10.1002/ACR.23177]

[6] Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy [J].

Eigentler, Thomas K. ;

Hassel, Jessica C. ;

Berking, Carola ;

Aberle, Jens ;

Bachmann, Oliver ;

Gruenwald, Viktor ;

Kaehler, Katharina C. ;

Loquai, Carmen ;

Reinmuth, Niels ;

Steins, Martin ;

Zimmer, Lisa ;

Sendl, Anna ;

Gutzmer, Ralf .

CANCER TREATMENT REVIEWS, 2016, 45 :7-18

[7] Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways [J].

Fife, Brian T. ;

Bluestone, Jeffrey A. .

IMMUNOLOGICAL REVIEWS, 2008, 224 :166-182

[8] Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4 [J].

Goldstein, Barbara L. ;

Gedmintas, Lydia ;

Todd, Derrick J. .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (03) :768-769

[9] Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center [J].

Horvat, Troy Z. ;

Adel, Nelly G. ;

Thu-Oanh Dung ;

Momtaz, Parisa ;

Postow, Michael A. ;

Callahan, Margaret K. ;

Carvajal, Richard D. ;

Dickson, Mark A. ;

D'Angelo, Sandra P. ;

Woo, Kaitlin M. ;

Panageas, Katherine S. ;

Wolchok, Jedd D. ;

Chapman, Paul B. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) :3193-+

[10] Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma [J].

Kyllo, Rachel L. ;

Parker, Mary Kendall ;

Rosman, Ilana ;

Musiek, Amy C. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (04) :E85-E86